Background: Perioperative neurocognitive disorders (PND) result in long-term morbidity and mortality with no effective interventions available. Because interleukin-6 (IL-6), a pro-inflammatory cytokine, is consistently up-regulated by trauma, including after surgery, we determined whether IL-6 is a putative therapeutic target for PND in a mouse model. Methods: Following institutional approval, adult (12e14 weeks) male C57/Bl6 mice were pretreated with the IL-6 receptor (IL6R) blocking antibody tocilizumab prior to open tibia fracture with internal fixation under isoflurane anaesthesia. Inflammatory and behavioural responses in a trace fear conditioning (TFC) paradigm were assessed postoperatively. Separately, the effects of IL-6 administration or of depletion of bone marrow-derived monocytes (BM-DMs) with clodrolip on the inflammatory and behavioural responses were assessed. Blood brain barrier disruption, hippocampal microglial activation, and infiltration of BM-DMs were each assessed following IL-6 administration. Results: The surgery-induced decrement in freezing time in the TFC assay, indicative of cognitive decline, was attenuated by tocilizumab (P<0.01). The surgery-induced increase in pro-inflammatory mediators was significantly reduced by tocilizumab. Exogenously administered IL-6 significantly impaired freezing behaviour (P<0.05) and up-regulated proinflammatory cytokines; both responses were prevented by depletion of BM-DMs. IL-6 disrupted the blood brain barrier, and increased hippocampal activation of microglia and infiltration of BM-DMs. Conclusions: IL-6 is both necessary and sufficient to produce cognitive decline. Following further preclinical testing of its perioperative safety, the IL6R blocker tocilizumab is a candidate for prevention and/or treatment of PND.
Editor's key points
A mouse model of postoperative surgical trauma (tibial fracture) was used to determine the role of interleukin-6 (IL-6) in postoperative cognitive dysfunction. Tocilizumab, an approved IL-6 receptor blocking antibody, prevented surgical traumaeinduced behavioural deficits and increases in inflammatory mediators. Exogenous IL-6 reproduced the behavioural and inflammatory effects of tibial fracture. Therapeutic interruption of the IL-6 pathway provides a potential strategy for prevention and treatment of postoperative cognitive disorders.
Perioperative neurocognitive disorders (PND), encompassing both postoperative delirium and postoperative cognitive dysfunction, complicate postoperative recovery with serious consequences. 1, 2 The pathophysiologic processes of PND, and hence possible targets for therapeutic intervention, need to be determined. A growing body of evidence, mainly from animal models of PND, suggests that the innate immune system is engaged through trauma-provoked release of damage associated molecular patterns (DAMPS) that initiate a peripheral inflammatory response. 3 Circulating pro-inflammatory cytokines are sensed by the central nervous system (CNS) through neural mechanisms, 4 resulting in complementary neuroinflammation through a disrupted blood brain barrier, 5 and producing microglial activation 6 with elaboration and release of pro-inflammatory cytokines and chemokines that are capable of disrupting long-term potentiation (LTP), 7 a biologic correlate of learning and memory. 8 Recent clinical studies reveal that neuroinflammation also occurs in the immediate postoperative period following peripheral surgery.
9e11
The pro-inflammatory cytokine, interleukin-6 (IL-6), is upregulated in both the periphery and CNS following experimental trauma in preclinical models, 12 and in surgical patients. 9 Circulating IL-6 levels positively correlate with deficits in cognition in humans. 13, 14 An observational study suggested that up-regulated postoperative IL-6 levels are associated with subsequent development of short-and medium-term impairment of cognitive function after surgery. 15 Administration of IL-6 diminished LTP in a hippocampal slice preparation 16 and lipopolysaccharide-induced decline in cognitive behaviour was attenuated in IL-6 deficient mice. 17 Interestingly, IL-6 neutralizing antibodies can improve postoperative cognitive impairment in aged mice. 18 These findings suggest that IL-6 might be an important factor that both facilitates immune-to-brain communication and hippocampal inflammatory mechanisms that negatively affect cognitive processing. We investigated whether IL-6 is both necessary and sufficient to produce cognitive decline in a mouse model of PND. If so, IL-6 could be an important target for therapeutic intervention to prevent or attenuate the development of PND. Four groups of randomly-assigned mice were treated with either saline or an intraperitoneal (i.p.) injection of tocilizumab, an antibody directed against the interleukin-6 (IL-6) receptor (IL6R) followed by tibial fracture or sham surgery 2 h later. Thirty min prior to tibia fracture/sham, the training session for trace fear conditioning (TFC) was performed and context testing was undertaken 72 h later. (B) Four groups of mice were prepared as for A. Six h after surgery or sham, mice were killed and blood and brain were harvested. (C) Mice were randomly assigned into four groups and treated with i.p. injection of clodrolip in a liposome emulsion or liposome emulsion only 1 h before TFC training session. This was followed by an i.p injection of IL-6 (IL6A) or saline control after training session and thereafter context testing was performed 72 h later. (D) Four groups of mice were prepared as for C. Six h after IL6A, mice were killed and blood and brain were harvested. 
Methods

Animals
Trace-fear conditioning
Trace-fear conditioning (TFC) was used to assess learning and memory as previously described. 3, 5, 6, 12 Briefly, animals were trained to associate a conditional stimulus (tone) with an aversive, unconditional stimulus (foot-shock). Aversive memory is associated with freezing behaviour when the mouse is re-exposed to the same context. The behavioural study was conducted using a conditioning chamber (Med Associates Inc., St. Albans, VT, USA) and an unconditional stimulus (two periods of 2-s foot-shock of 0.75 mA). Behaviour was captured with an infrared video camera (Video Freeze; Med Associates Inc.). After a particular intervention, animals underwent a training session and were then returned to their cage. Mice underwent a context test 72 h after training, during which no tones or foot-shocks were delivered. Lack of movement, indicating freezing behaviour, of video-recordings was analysed. Memory impairment is indicated by a decrease in freezing time.
Systemic inflammatory response
Blood was collected transcardially 6 h after aseptic surgical trauma via thoracotomy under terminal isoflurane anaesthesia. Blood was collected into heparin-coated syringes and samples were centrifuged at 1200Â g for 10 min; plasma was collected and stored at À80 C until assayed. Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to measure plasma IL-6, IL-1b, and monocyte chemoattractant protein-1 (MCP-1) according to manufacturer's instructions (R&D Systems, Minneapolis, Minnesota, USA).
Neuroinflammatory response
Mice were perfused 3, 5, 6, 12 with phosphate buffered saline and the hippocampus harvested 6 h after surgery. Samples were rapidly extracted and stored at À80 C until assayed. IL-6, IL-1b, and MCP-1 levels in the hippocampus were measured with ELISA assays and total protein concentration was assessed using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). , BD Biosciences, San Jose California, USA) for 1 h at room temperature, these were incubated with rabbit antibody directed against murine albumin (ab207327, Abcam, Burlingame, California, USA) at 1:1000 dilution overnight at 4 C. For loading control, rabbit Pre-emptive blockade of interleukin-6 (IL-6) receptor (IL6R) prevents postoperative decrement in freezing behaviour. Four groups of randomly-assigned mice (n¼10) were treated with either saline or an intraperitoneal injection of tocilizumab, an antibody directed against the IL-6 receptor (IL6R) followed by tibia fracture or sham surgery 2 h later. Thirty min prior to tibia fracture/sham, the training session for TFC was performed and context testing for freezing behaviour was undertaken 72 h later. Data are expressed as means (SEM) and compared by oneway analysis of variance and Student-Newman-Keuls test. *P<0.01. monoclonal antibody against murine Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (ab181602, Abcam) was used. After washing four times with Tris buffered saline (TBS) containing 0.1% Tween 20 (TBST), membranes were incubated with 1:10 000 IRDye 680RD or 800RD labelled goat anti-rabbit antibody (LICOR ® ) for 1 h at room temperature. Membranes were washed three times with TBST and once with TBS, and images were captured and quantified using a LI-COR Imager (LICOR ® , Biosciences).
Permeability of the blood brain barrier
Hippocampal infiltration of CCR2þ cells and activation of microglia
Ccr2RFP/þ Cx3cr1GFP/þ mice were administered IL-6 50 mg/kg and 6 h later were sacrificed and perfused with saline followed by 4% paraformaldehyde in 100 mM phosphate buffer to assess infiltration of CCR2-expressing cells and activation of microglia as described. 6 
Interventions
The experimental protocol is depicted in Fig. 1 .
Depletion of bone marrow-derived monocytes
Clodrolip is a liposomal formulation of encapsulated clodronate (dichloromethylene bisphosphonic acid) that is ingested and digested by phagocytes, followed by intracellular release 
Statistical analysis
GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA, USA) statistical package and Stata 11.2 software (StataCorp, College Station, TX, USA) were used for statistical analysis. Results are expressed as mean (SD). Data were compared using analysis of variance whenever there was a possibility of interaction between independent treatment variables, and prior to performing individual pairwise comparisons by Newman-Keuls post hoc test wherever appropriate. In each case, P<0.05 was considered significant.
Results
IL6R blocker can abolish cognitive decline induced by surgery
Cognitive decline was induced by surgery as evidenced by a significant reduction in freezing time [25 (12) % vs 56 (15)%, P<0.01; Fig. 2 ). Pre-emptive exposure to tocilizumab (IL6R antibody) attenuated surgery-induced freezing behaviour [51 (14)% vs 25 (12)%, P<0.01; Fig. 2) , and the response to tocilizumab alone was not significantly different from that of the sham control group [62 (9)% vs 56 (15)%; Fig. 2 ).
IL6R blocker reduces systemic and neuroinflammatory response to surgery
After surgery, there was a significant (P<0.01) increase of both plasma IL-6 ( Fig. 3A) and MCP-1 (Fig. 3B ) at 6 h. While IL6R blockade with tocilizumab prevented the surgery-induced increase in plasma MCP-1 (Fig. 3B) , there was a further increase in circulating IL-6 (Fig. 3A) . Surgery significantly (P<0.01) increased hippocampal IL-6 ( Fig. 3C ) and MCP-1 (Fig. 3D) ; both responses were prevented by IL6R blockade.
IL-6 causes cognitive decline through involvement of BM-DMs
At 3 days after IL-6 50 mg kg À1 there was a decrement in freezing behaviour [59 (13)% vs 39 (12)%; P<0.01) that was prevented by prior depletion of BM-DMs by clodrolip pretreatment; control liposomes alone had no reversal effect (Fig. 4 ).
IL-6 produces systemic and hippocampal inflammation through involvement of BM-DMs
At 6 h after administration of 50 mg kg À1 IL-6, circulating IL-6
( Fig. 5A) , circulating IL-1b (Fig. 5B) , hippocampal IL-6 (Fig. 5C) , and hippocampal IL-1b (Fig. 5C) were each significantly increased. In each case the IL-6-induced incremental change was precluded by depletion of BM-DMs with clodrolip. Interestingly, although both circulating (Fig. 5E ) and hippocampal ( Fig. 5F ) MCP-1 were each increased by IL-6, the incremental change was not attenuated by clodrolip.
IL-6 disrupts the blood brain barrier
At 6 h after administration of 50 mg kg À1 IL-6, the amount of albumin that penetrated into the brain was significantly greater than in control mice (Fig. 6 ).
IL-6 promotes hippocampal infiltration of CCR2-expressing monocytes and activation of microglia
At 6 h after administration of 50 mg kg À1 IL-6, there was an increase in the number of CCR2-expressing BM-DMs with no change in the number of CX3CR1-expressing microglia ( Fig. 7A and B). The number of large (Fig. 7C ) and high intensity (Fig. 7D ) Iba1-stained microglia, indicative of transition to an activated pro-inflammatory state, increased following IL-6 administration.
Discussion
IL-6 is both necessary and sufficient to produce postoperative neurologic dysfunction
As DAMPs, cytokines, and chemokines are up-regulated by the aseptic trauma of surgery, 3, 5, 6, 9, 12 we have addressed which are necessary and sufficient to produce the co-ordinated response that results in postoperative neurologic dysfunction (PND). We now report a requirement for the cytokine IL-6, because interruption of its signalling pathway through a neutralizing antibody to the IL6R (tocilizumab) prevents PND. Furthermore, since administration of IL-6 alone produces PND, this cytokine is sufficient to produce the post-surgical phenotype of cognitive decline. These data do not rule out that other molecules up-regulated following trauma might also be necessary and sufficient. In fact, we have demonstrated that the same is true for the DAMP high molecular group box protein 1 (HMGB1). 3 Why are different molecules performing the same function? It is possible that the timing at which these are released (HMGB1 within 1 h and IL-6 from 6 h) 3, 5, 12 results in a more concerted response. Furthermore, because the inflammatory response to surgery is so crucial, some redundancy might be required to ensure that these processes are always activated.
IL6R antibody decreases inflammatory response without changing circulating IL-6 expression
Because systemic and hippocampal inflammation are required for the development of PND and because tocilizumab prevents the development of PND, it was anticipated that IL6R blockade would dampen the inflammatory response to surgery. However, surgery-induced upregulation of circulating IL-6 levels was further enhanced by tocilizumab. A possible explanation is that an intervention that interferes with IL-6 signalling induces a feed-forward response to overcome the blockade. Another possibility is the cytokine release syndrome that has been observed clinically when certain types of immunotherapy are administered. 19 However, there is preliminary evidence that tocilizumab may be used to ameliorate cytokine release syndrome induced by other biologics.
20
Depletion of BM-DMs can prevent IL-6 induced PND and inflammation
We have reported a role for circulating BM-DMs in the development of trauma-induced 21 and HMGB1-induced PND. 3 It is relevant that elimination of these cells prevents IL-6 induced PND and inflammatory markers in the circulation and hippocampus. Yet MCP-1, the crucial chemokine that attracts BM-DMs into brain to propagate neuroinflammation, was not down-regulated by a perturbation that prevents hippocampal inflammation. This observation is consistent with our previous report that the up-regulated MCP-1 levels that are evident after surgery 9 are Fig 5. Depletion of bone marrow-derived monocytes prevents interleukin-6 (IL-6) induced inflammatory response. Two groups of randomly-assigned mice (n¼8) were treated with either saline or an intraperitoneal (i.p.) injection of IL-6 (IL6A). Two groups of randomlyassigned mice (n¼8) were pre-treated with liposomes containing clodronate (clodrolip) or liposomes without clodronate followed by injection of IL-6 (IL6A) 1 h later. Six h after treatment, mice were killed and blood and brain were harvested and assayed for circulating IL-6 (A), circulating IL-1b (B), hippocampal IL-6 (C), and hippocampal IL-1b (D), circulating MCP-1 (E), and hippocampal monocyte chemoattractant protein-1 (MCP-1) (F). Data were analysed by one way analysis of variance followed by Student-Newman-Keuls test. *P<0.05; **P<0.01.
unaltered by depletion of BM-DMs in an HMGB1-induced surgical phenotype. 3 Therefore, these data provide further evidence that MCP-1 does not originate from BM-DMs. Our recent description of the interaction between BM-DMs and microglia raises the possibility that MCP-1 originates from microglia, although the signal that initiates this remains elusive. 6 IL-6 promotes hippocampal activation of microglia and infiltration of CCR2þ BM-DMs
Previously, we reported that peripheral surgery disrupts the blood brain barrier and promotes infiltration of CCR2-expressing BM-DMs 5 and activation of microglia. 6 Now we demonstrate that these crucial steps necessary for PND can be mediated by exogenously administered IL-6.
Limitations
Tocilizumab is a humanized anti-IL6R monoclonal antibody with cross-reactivity against the murine IL6R with no untoward effects reported. IL-6 is an animal-free recombinant protein produced in Escherichia coli. Notwithstanding their longstanding use, these reagents could have hitherto unknown off-target effects giving rise to spurious findings. 
IL-6 signalling pathways
Transmembrane signal transduction of IL-6 can be propagated by at least two discrete pathways. In classic signalling, IL-6 stimulates a limited number of target cells 22 including hepatocytes, neutrophils, and CD4þ T-cells 23, 24 that express membrane-bound IL6R (mIL6R), which, following ligand binding, dimerizes with the signalling receptor protein gp130 leading to regenerative and protective effects. Most cells express gp130 and not mIL6R, and are therefore unresponsive to IL-6 alone. Circulating soluble IL6R (sIL6R) constitutes an alternative binding target for IL-6. The resulting IL-6/sIL6R complex binds to gp130 to initiate the 'trans-signalling' pathway resulting in proinflammatory effects. 25, 26 Neurones and astrocytes respond to the IL-6/sIL6R complex but not to IL-6 alone, suggesting that trans-signalling is crucial for mediating the pro-inflammatory effects of IL-6 on these cells. 27e29 In contrast, microglia respond well to IL-6 alone via classic signaling. 30 As tocilizumab blocks the effects of both mIL6R and sIL6R 31 we can only speculate that it is blockade of sIL6R, and hence the trans-signalling pathway, that results in the ameliorative effects of tocilizumab on PND.
Future studies
Tocilizumab is clinically available and has been used in a variety of inflammation-related diseases, yet its possible future application in the perioperative setting to prevent PND needs to await further preclinical investigations. Firstly, it will be important to establish whether tocilizumab is effective when administered after the initiation of the injury. If not, then its pre-emptive utility will be limited to surgical patients whose high risk for PND is established by their underlying immunological phenotype. Secondly, like all biologics, it needs to be established whether perioperative use of tocilizumab increases the risk for acquiring and responding appropriately to infections. Finally, inflammation is a sine qua non for healing. Therefore, the effects of tocilizumab on surgical wound healing will need to be investigated.
Conclusions
IL-6 is necessary and sufficient to produce postoperative neurological dysfunction in mice. Even though tocilizumab is licensed for indications such as rheumatoid arthritis and giant cell arteritis, the clinical application of strategies designed to disable IL6R signalling must await further preclinical efficacy and safety testing.
